R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
Phospho-Jak2 (Tyr1008) (D4A8) Rabbit mAb #8082
Filter:
- WB
Supporting Data
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 125 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
Phospho-Jak2 (Tyr1008) (D4A8) Rabbit mAb recognizes endogenous levels of Jak2 protein only when phosphorylated at Tyr1008. This antibody also reacts with Jak2 when dually phosphorylated at Tyr1007 and Tyr1008. Cross-reactivity was not observed with other Jak family members by western blot.
Species Reactivity:
Human, Mouse
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Rat, Monkey, Xenopus, Bovine, Pig
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr1008 of human Jak2 protein.
Background
Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and phosphorylate their associated receptors to provide multiple binding sites for signaling proteins. These associated signaling proteins, such as Stats (2), Shc (3), insulin receptor substrates (4), and focal adhesion kinase (FAK) (5), typically contain SH2 or other phospho-tyrosine-binding domains.
Jak2 signaling is associated with a number of cytokines, growth factors, and hormones including IL-3, IL-5, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO) growth hormone, prolactin, and leptin (6-13). The oncogenic potential of Jak2 has been realized though translocations and point mutations resulting in its enhanced, de-regualated kinase activity, making Jak2 a potential therapeutic target. Jak2 gene translocations resulting in fusions with the TEL (TEL-JAK2) and PCM1 (PCM1-JAK2) have been found in leukemia patients (14,15). An activating point mutation in Jak2 resulting in a valine to phenylalanine switch at position 617 (V617F) has been implicated in myeloproliferative disorders including polycythemia vera and essential thrombocythemia (16).
Jak2 signaling is associated with a number of cytokines, growth factors, and hormones including IL-3, IL-5, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO) growth hormone, prolactin, and leptin (6-13). The oncogenic potential of Jak2 has been realized though translocations and point mutations resulting in its enhanced, de-regualated kinase activity, making Jak2 a potential therapeutic target. Jak2 gene translocations resulting in fusions with the TEL (TEL-JAK2) and PCM1 (PCM1-JAK2) have been found in leukemia patients (14,15). An activating point mutation in Jak2 resulting in a valine to phenylalanine switch at position 617 (V617F) has been implicated in myeloproliferative disorders including polycythemia vera and essential thrombocythemia (16).
- Leonard, W.J. and O'Shea, J.J. (1998) Annu Rev Immunol 16, 293-322.
- Darnell, J.E. (1997) Science 277, 1630-5.
- VanderKuur, J. et al. (1995) J Biol Chem 270, 7587-93.
- Argetsinger, L.S. et al. (1995) J Biol Chem 270, 14685-92.
- Zhu, T. et al. (1998) J Biol Chem 273, 10682-9.
- Quelle, F.W. et al. (1994) Mol Cell Biol 14, 4335-41.
- Witthuhn, B.A. et al. (1993) Cell 74, 227-36.
- Tortolani, P.J. et al. (1995) Blood 85, 3444-51.
- Pallard, C. et al. (1995) EMBO J 14, 2847-56.
- Narazaki, M. et al. (1994) Proc Natl Acad Sci USA 91, 2285-9.
- Argetsinger, L.S. et al. (1993) Cell 74, 237-44.
- Rui, H. et al. (1994) J Biol Chem 269, 5364-8.
- Ghilardi, N. and Skoda, R.C. (1997) Mol Endocrinol 11, 393-9.
- Lacronique, V. et al. (1997) Science 278, 1309-12.
- Reiter, A. et al. (2005) Cancer Res 65, 2662-7.
- Kralovics, R. et al. (2005) N Engl J Med 352, 1779-90.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Jak antibodies produced under license (granting certain rights including those under U.S. Patent No. 5,658,791) from Chemicon International, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.